年轻起病与晚发2型糖尿病的比较:英国前瞻性糖尿病研究(UKPDS)长达30年随访分析(UKPDS 92)
该研究利用UKPDS 1977至2007年数据,纳入4550例自身抗体阴性的新诊断2型糖尿病患者,比较40岁前起病(429例,9.4%)与40岁及以上起病者的并发症和死亡率。年轻起病组标准化死亡比更高(3.72 vs 1.54),且在任一年龄段,任何糖尿病相关终点、全因死亡、微血管病变和心肌梗死的5年发病率均随诊断年龄年轻化而升高。
要点
- 年轻起病2型糖尿病(<40岁)标准化死亡比3.72(95%CI 2.98-4.64),高于晚发组1.54(1.47-1.61)。
- 除微血管病变外,晚发组所有结局粗发病率更高;但任一年龄段,年轻起病组5年发病率更高。
- 年轻起病组前20年年均HbA1c更高,强化与常规血糖控制间无亚组交互作用。
核心结论
- 相对于一般人群的死亡风险在较年轻诊断2型糖尿病者中更高,年轻起病2型糖尿病并发症风险增加和血糖控制更差,呼吁发展服务以识别和管理这些个体。
研究设计与样本
- 研究使用UKPDS 1977至2007年收集的数据,纳入年龄25-65岁、新诊断2型糖尿病且无糖尿病自身抗体的参与者,分为年轻起病(<40岁)与晚发(≥40岁)。
- 共4550例参与者自身抗体检测阴性,其中429例(9.4%)为年轻起病2型糖尿病;2704例(59.4%)为男性,平均HbA1c为76 mmol/mol(SD 24.6)。
- 中位随访17.5年(IQR 12.7-20.8),使用英国一般人群数据计算标准化死亡比(SMR),并按诊断时10岁年龄区间分析预设结局的发病率。
主要发现
- 年轻起病2型糖尿病SMR为3.72(95%CI 2.98-4.64),高于晚发2型糖尿病的1.54(95%CI 1.47-1.61)。
- 除微血管病变外,晚发2型糖尿病所有结局的发病率更高;微血管病变发病率为年轻起病14.5(11.9-17.7) vs 晚发12.1(11.3-13.0)每1000人年。
- 在任一年龄,任何糖尿病相关终点、全因死亡、微血管病变和心肌梗死的5年发病率均随诊断年龄更年轻而更高。
- 年轻起病组前20年年均HbA1c高于晚发组。
- 在随机接受强化与常规血糖控制的参与者中,年轻起病与晚发2型糖尿病亚组对任何结局均未观察到交互作用。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Younger-onset type 2 diabetes is associated with accelerated complications. We assessed whether complications and mortality rates differed for younger age compared with older age at diagnosis over 30 years of follow-up. METHODS: In this study, we used data from the UKPDS, collected between 1977 and 2007, of participants aged 25-65 years with newly diagnosed type 2 diabetes with younger-onset (younger than 40 years) or later-onset (40 years or older), and without diabetes autoantibodies. We analysed standardised mortality ratios (SMR) using UK general population data, and incidence rates of prespecified outcomes by 10-year age intervals at diagnosis. FINDINGS: Of 4550 participants testing negative to all measured autoantibodies, 429 (9·4%) had younger-onset type 2 diabetes. 2704 (59·4%) were male, and mean HbA1c was 76 mmol/mol (SD 24·6). The median follow-up was 17·5 years (IQR 12·7-20·8). SMR for younger-onset type 2 diabetes was higher (3·72 [95% CI 2·98-4·64]) compared with later-onset type 2 diabetes (1·54 [1·47-1·61]). The incidence rate was higher for all outcomes in later-onset type 2 diabetes, except for microvascular disease (younger-onset 14·5 (11·9-17·7) vs later-onset 12·1 (11·3-13·0) per 1000 person-years). However, at any given age, the 5-year incidence of any diabetes-related endpoint, all-cause mortality, microvascular disease, and myocardial infarction was higher with younger age at diagnosis. Annual mean HbA1c was higher in the first 20 years in younger-onset compared with later-onset type 2 diabetes. Among participants randomised to intensive versus conventional glycaemic control, we observed no interactions by subgroup of younger-onset versus later-onset type 2 diabetes for any outcome. INTERPRETATION: The risk of dying relative to the general population is even greater for people diagnosed with type 2 diabetes at younger ages. The increased risk of complications and poorer glycaemic control in younger-onset type 2 diabetes calls for the development of services to identify and manage these individuals. FUNDING: National Institute of Health and Care Research's Biomedical Research Centre.
引用
- Lin B, Coleman RL, Bragg F, et al. Younger-onset compared with later-onset type 2 diabetes: an analysis of the UK Prospective Diabetes Study (UKPDS) with up to 30 years of follow-up (UKPDS 92). Lancet Diabetes Endocrinol. 2024. PMID: 39461360. doi:10.1016/S2213-8587(24)00242-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。